Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the company to lose more than 40% of their value in pre-market trading. The news is ...
News Medical on MSN
CIRM awards $7.4 million to advance stem cell-based gene therapy for Friedreich's ataxia
The California Institute for Regenerative Medicine (CIRM) has awarded $7.4 million to support a University of California San Diego team developing a first-of-its-kind stem cell-based gene therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback